Caution is advised when consuming alcohol with Raha 20. Please consult your doctor.
CONSULT YOUR DOCTOR
Raha 20 may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
CONSULT YOUR DOCTOR
Raha 20 is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
CONSULT YOUR DOCTOR
It is not known whether Raha 20 alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
SAFE IF PRESCRIBED
Raha 20 is safe to use in patients with kidney disease. No dose adjustment of Raha 20 is recommended.
Raha 20 should be used with caution in patients with severe liver disease. Dose adjustment of Raha 20 may be needed. Please consult your doctor.
Raha 20 is a medicine that reduces the amount of acid produced in your stomach. It is used for treating acid-related diseases of the stomach and intestine such as heartburn, acid reflux, peptic ulcer disease, and some other stomach conditions associated with excessive acid production. Raha 20 is also used to prevent stomach ulcers and acidity that may be seen with the prolonged use of pain-killers. It belongs to a class of medicines known as proton pump inhibitors (PPIs). This medicine should be taken one hour before a meal, preferably in the morning. The dose will depend on your underlying condition and how you respond to the medicine. Try to take it regularly at the same time each day as advised by your doctor. You should keep on taking it as prescribed even if your symptoms disappear quickly. You may be able to help improve your symptoms by eating smaller meals more often and avoiding caffeinated drinks like tea and coffee, and spicy or fatty foods. The most common side effects that may be seen with this medicine include nausea, vomiting headache, dizziness, flatulence, diarrhea, and stomach pain. These tend to be mild but talk to your doctor if they bother you or do not go away. The risk of side effects may increase the longer you take this medicine. Long-term use (more than 1 year) may increase your risk for bone fractures, especially with higher doses. Talk to your doctor about ways to prevent bone loss (osteoporosis), like taking calcium and vitamin D supplements. Low blood magnesium levels (hypomagnesemia) have been seen in some people taking this medicine for 3 months or more. This may lead to tiredness, confusion, dizziness, muscle twitches, and an irregular heartbeat. Your doctor may monitor your magnesium levels to prevent this. Raha 20 is not suitable for some people. Before taking this medicine, you need to tell your doctor if you have severe liver problems, are taking medicines for HIV, have ever had an allergic reaction to similar medicines in the past or suffer from bone loss (osteoporosis). Pregnant or breastfeeding women should also consult their doctor before taking it. Avoid drinking alcohol as it makes your stomach produce excessive acid and can worsen your symptoms. Do not drive or use machinery or tools, if this medicine makes you feel dizzy or sleepy.
Uses of Raha 20
- Gastroesophageal reflux disease (Acid reflux)
- Peptic ulcer disease
Side effects of Raha 20
- Sore throat
- Stomach pain
How to use Raha 20
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Raha 20 is to be taken empty stomach.
How Raha 20 works
Raha 20 is a proton pump inhibitor (PPI). It works by reducing the amount of acid in the stomach which helps in relief of acid related indigestion and heartburn.
What if you forget to take Raha 20?
If you miss a dose of Raha 20, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
- It is a well-tolerated medicine and provides relief for a long time.
- Avoid eating late at night or before bedtime.
- Inform your doctor if you get watery diarrhea, fever or stomach pain that does not go away.
- Inform your doctor if you do not feel better after taking it for 14 days as you may be suffering from some other problem that needs attention.
- Long-term use of Raha 20 can cause weak bones and a deficiency of minerals such as magnesium. Take adequate dietary intake of calcium and magnesium or their supplements as prescribed by your doctor.
- Consult your doctor right away if you develop decreased urination, edema (swelling due to fluid retention), lower back pain, nausea, fatigue, and rash or fever. These could be signs of a kidney problem.
Peptic ulcer disease, H. pylori infection, Gastro-oesophageal reflux disease, Paediatric GERD
Administer with or without meals
Oral Gastro-oesophageal reflux disease Adult: 20 mg daily for 4-8 wk. Maintenance: 10 or 20 mg/day. All doses to be taken once in the morning. Zollinger-Ellison syndrome Adult: Initially, 60 mg once in the morning, adjusted to max dose of 120 mg/day if needed. Daily doses >100 mg should be given in 2 divided doses. Peptic ulcer Adult: 20 mg once in the morning for 4-8 wk (duodenal ulcer) or for 6-12 wk (gastric ulcer). H.pylori infection Adult: 1-wk triple therapy: 20 mg bid combined w/ clarithromycin 500 mg bid and amoxicillin 1 g bid or combined w/ clarithromycin 250 mg bid and metronidazole 400 mg bid. Erosive oesophagitis Adult: 20 mg/day for 4-8 wk. May continue for another 8 wk if healing is incomplete. Maintenance: 10 or 20 mg/day. All doses to be taken once in the morning. Elderly: No dosage adjustment needed. Hepatic impairment: No dosage adjustment needed.
Delayed-release capsule (sprinkles) <1 year: Safety and efficacy not established 1-11 years (<15 kg): 5 mg PO qDay 30 minutes before a meal, for up to 12 weeks; may increase to 10 mg/day if inadequate response 1-11 years (>15 kg): 10 mg PO qDay 30 minutes before a meal, for up to 12 weeks Gastroesophageal Reflux Disease Delayed-release tablet <12 years: Safety and efficacy not established >12 years: 20 mg PO qDay for up to 8 weeks
Renal impairment: No dosage adjustment needed.
Rabeprazole is contraindicated in patients with known hypersensitivity to Rabeprazole, other PPIs or to any component of the formulation.
Mode of Action
Rabeprazole is a PPI that suppresses gastric acid secretion by inhibiting H+/K+ ATPase at the secretory surface of the gastric parietal cell.
Gastric malignancy should be ruled out. Severe hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor Mg levels prior to initiation and periodically during prolonged use. Lactation Risk Summary Lactation studies have not been conducted to assess presence in human milk, effects on breastfed infant, or effects on milk production; drug is present in rat milk; development and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from drug or from underlying maternal condition
1-10% Headache (2-10%),Constipation (2%),Diarrhea (2-5%),Flatulence (3%),Pain (3%),Pharyngitis (3%),Abdominal pain (4%) <1% Agitation,Agranulocytosis,Alopecia,Anemia,Angioedema,Chest pain,Delirium,Erythema,Hypokalemia,Hypomagnesemia,Hyponatremia,Jaundice,Leukocytosis,Leukopenia,Migraine,Osteoporosis related fracture,Rhabdomyolysis,Stevens-Johnson syndrome,Sudden death,Toxic epidermal necrolysis,Abnormal taste
Pregnancy Category Note
Risk Summary There are no available human data in pregnant women to inform drug associated risk; background risk of major birth defects and miscarriage for indicated populations are unknown; however, background risk in U.S. general population of major birth defects is 2-4% and of miscarriage is 15- 20% of clinically recognized pregnancies; no evidence of adverse developmental effects were seen in animal reproduction studies with rabeprazole administered during organogenesis at 13 and 8 times human area under plasma concentration-time curve (AUC) at recommended dose for GERD, in rats and rabbits, respectively; Changes in bone morphology were observed in offspring of rats treated with oral doses of different PPI through most of pregnancy and lactation; when maternal administration was confined to gestation only, there were no effects on bone physeal morphology in offspring at any age
May decrease serum concentration of ketoconazole, itraconazole and clopidogrel. Increased risk of hypomagnesaemia w/ diuretics and digoxin. May increase prothrombin time and INR of warfarin. May increase plasma concentration of saquinavir and methotrexate. Decreased serum levels w/ sucralfate. Potentially Fatal: May decrease plasma concentrations and pharmacological effects of rilpivirine and atazanavir.
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.